Matthew Strobeck News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Matthew strobeck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Matthew Strobeck Today - Breaking & Trending Today

Biodesix, Inc. (NASDAQ:BDSX) Expected to Post Quarterly Sales of $8.60 Million

Wall Street brokerages expect that Biodesix, Inc. (NASDAQ:BDSX – Get Rating) will report $8.60 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Biodesix’s earnings, with estimates ranging from $8.11 million to $8.90 million. Biodesix reported sales of $11.89 million during the same quarter last year, which […] ....

United States , Matthew Strobeck , John Patience , Morgan Stanley , Chicago Capital , Zacks Investment Research , Biodesix Inc , Biodesix Company Profile Get Rating , Canaccord Genuity Group , Millennium Management , Wall Street , Get Rating , Investment Research , Genuity Group , Director Matthew Strobeck , Chairman John Patience , Capital Management , Sigma Investments , Company Profile , Nodify Lung Nodule Risk Assessment , Nasdaq Bdsx ,

Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Buy" from Analysts

Biodesix, Inc. (NASDAQ:BDSX – Get Rating) has received an average recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among […] ....

United States , Matthew Strobeck , John Patience , Geode Capital Management , Zacks Investment Research , Biodesix Inc , Blackrock Inc , De Shaw Co , Jpmorgan Chase Co , Wells Fargo Company , Canaccord Genuity Group , Get Rating , Marketbeat Ratings , Investment Research , Chairman John Patience , Director Matthew Strobeck , Capital Management , Nodify Lung Nodule Risk Assessment , Nasdaq Bdsx ,

Biodesix, Inc. (NASDAQ:BDSX) Expected to Announce Quarterly Sales of $8.60 Million

Equities analysts expect that Biodesix, Inc. (NASDAQ:BDSX – Get Rating) will report sales of $8.60 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Biodesix’s earnings, with the lowest sales estimate coming in at $8.11 million and the highest estimate coming in at $8.90 million. Biodesix reported sales of $11.89 […] ....

United States , Matthew Strobeck , John Patience , Morgan Stanley , Geode Capital Management , Securities Exchange Commission , Zacks Investment Research , Biodesix Inc , Biodesix Company Profile Get Rating , Canaccord Genuity Group , Citadel Advisors , Get Rating , Investment Research , Genuity Group , Director Matthew Strobeck , Exchange Commission , Chairman John Patience , Capital Management , Two Sigma Investments , Company Profile , Nodify Lung Nodule Risk Assessment , Nasdaq Bdsx ,

Biodesix, Inc. (NASDAQ:BDSX) Expected to Announce Earnings of -$0.36 Per Share

Wall Street brokerages expect Biodesix, Inc. (NASDAQ:BDSX – Get Rating) to announce earnings of ($0.36) per share for the current quarter, Zacks reports. Three analysts have made estimates for Biodesix’s earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.47). Biodesix reported earnings of ($0.41) per share during the same quarter last year, […] ....

United States , Matthew Strobeck , John Patience , Morgan Stanley , Geode Capital Management , Securities Exchange Commission , Zacks Investment Research , Biodesix Inc , Canaccord Genuity Group , Citadel Advisors , Wall Street , Get Rating , Genuity Group , Investment Research , Director Matthew Strobeck , Exchange Commission , Chairman John Patience , Capital Management , Two Sigma Investments , Nodify Lung Nodule Risk Assessment , Nasdaq Bdsx ,

10 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital

In this article, we discuss 10 biotech stocks to buy according to Matthew Strobeck s Birchview Capital. ....

United States , Ed Arce , Matthew Strobeck Birchview , Carter Gould , Chris Schott , Michael Yee , Matthew Strobeck , Gobind Singh , Geoff Meacham , Regeneron Pharmaceuticals Inc , Albireo Pharma Inc , United Therapeutics Corporation , Number Of Hedge Fund Holders , Biogen Inc , Vertex Pharmaceuticals Incorporated , Exchange Commission , Merck Co Inc , University Of Cincinnati , Amgen Inc , Acceleron Pharma Inc , Prothena Corporation , Buy According , Westfield Capital Management , Thomas Weisel Asset Management , Birchview Capital , Regeneron Pharmaceuticals ,